Pfizer Inc. (NYSE:PFE - Free Report) - Investment analysts at Zacks Research reduced their Q1 2025 EPS estimates for shares of Pfizer in a research report issued to clients and investors on Thursday, January 2nd. Zacks Research analyst K. Shah now forecasts that the biopharmaceutical company will earn $0.61 per share for the quarter, down from their prior forecast of $0.68. The consensus estimate for Pfizer's current full-year earnings is $2.95 per share. Zacks Research also issued estimates for Pfizer's Q2 2025 earnings at $0.60 EPS, Q3 2025 earnings at $0.83 EPS, Q4 2025 earnings at $0.82 EPS, FY2025 earnings at $2.86 EPS, Q1 2026 earnings at $0.63 EPS, Q2 2026 earnings at $0.61 EPS and Q4 2026 earnings at $0.85 EPS.
Other equities analysts also recently issued reports about the stock. Evercore ISI upgraded shares of Pfizer to a "strong-buy" rating in a report on Wednesday, October 30th. Citigroup started coverage on shares of Pfizer in a research note on Friday, October 25th. They set a "neutral" rating and a $30.00 price objective for the company. StockNews.com lowered Pfizer from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, November 20th. Cantor Fitzgerald reissued an "overweight" rating and set a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. Finally, Wolfe Research began coverage on Pfizer in a research report on Friday, November 15th. They issued an "underperform" rating and a $25.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Pfizer currently has a consensus rating of "Moderate Buy" and a consensus target price of $32.15.
Get Our Latest Analysis on PFE
Pfizer Price Performance
Shares of PFE stock traded up $0.29 during mid-day trading on Monday, reaching $26.88. The stock had a trading volume of 43,915,106 shares, compared to its average volume of 36,742,000. The company has a market cap of $152.33 billion, a P/E ratio of 36.32, a price-to-earnings-growth ratio of 0.63 and a beta of 0.64. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer has a 12-month low of $24.48 and a 12-month high of $31.54. The business has a 50-day simple moving average of $26.33 and a 200 day simple moving average of $28.08.
Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to analysts' expectations of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm's quarterly revenue was up 31.2% compared to the same quarter last year. During the same period last year, the company posted ($0.17) earnings per share.
Pfizer Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.40%. The ex-dividend date is Friday, January 24th. This is an increase from Pfizer's previous quarterly dividend of $0.42. Pfizer's payout ratio is 232.43%.
Insiders Place Their Bets
In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of the business's stock in a transaction dated Wednesday, October 30th. The shares were acquired at an average price of $28.24 per share, with a total value of $28,240.00. Following the purchase, the director now owns 10,000 shares in the company, valued at approximately $282,400. The trade was a 11.11 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.06% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Pfizer
Several hedge funds and other institutional investors have recently bought and sold shares of PFE. Oliver Luxxe Assets LLC boosted its holdings in Pfizer by 2.2% in the fourth quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company's stock valued at $499,000 after purchasing an additional 401 shares during the last quarter. Neville Rodie & Shaw Inc. boosted its stake in shares of Pfizer by 8.7% during the 4th quarter. Neville Rodie & Shaw Inc. now owns 104,728 shares of the biopharmaceutical company's stock valued at $2,779,000 after buying an additional 8,365 shares during the last quarter. Pensionfund Sabic grew its position in shares of Pfizer by 41.7% during the fourth quarter. Pensionfund Sabic now owns 85,000 shares of the biopharmaceutical company's stock worth $2,255,000 after buying an additional 25,000 shares in the last quarter. Nordea Investment Management AB increased its stake in shares of Pfizer by 36.1% in the fourth quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company's stock worth $108,002,000 after buying an additional 1,080,822 shares during the last quarter. Finally, Central Pacific Bank Trust Division raised its holdings in Pfizer by 95.1% in the fourth quarter. Central Pacific Bank Trust Division now owns 18,118 shares of the biopharmaceutical company's stock valued at $481,000 after acquiring an additional 8,832 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.
About Pfizer
(
Get Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Recommended Stories
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
